Synthetic, cannabinoid-like compound
Abnormal cannabidiol |
|
|
4-[(1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
|
CAS Number | |
---|
PubChem CID | |
---|
ChemSpider | |
---|
UNII | |
---|
CompTox Dashboard (EPA) | |
---|
|
Formula | C21H30O2 |
---|
Molar mass | 314.469 g·mol−1 |
---|
3D model (JSmol) | |
---|
CCCCCC1=CC(=CC(=C1[C@H]2C=C(CC[C@H]2C(=C)C)C)O)O
|
InChI=1S/C21H30O2/c1-5-6-7-8-16-12-17(22)13-20(23)21(16)19-11-15(4)9-10-18(19)14(2)3/h11-13,18-19,22-23H,2,5-10H2,1,3-4H3/t18-,19-/m0/s1 YKey:YWEZXUNAYVCODW-OALUTQOASA-N Y
|
NY (what is this?) (verify) |
Abnormal cannabidiol (Abn-CBD) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces cell migration, cell proliferation and mitogen-activated protein kinase activation in microglia, but without producing any psychoactive or sedative effects.[1][2] Abn-CBD can be found as an impurity in synthetic cannabidiol.[3]
- ^ Adams MD, Earnhardt JT, Martin BR, Harris LS, Dewey WL, Razdan RK (September 1977). "A cannabinoid with cardiovascular activity but no overt behavioral effects". Experientia. 33 (9): 1204–1205. doi:10.1007/BF01922330. PMID 891878. S2CID 21488700.
- ^ McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM, et al. (March 2010). "N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor". BMC Neuroscience. 11: 44. doi:10.1186/1471-2202-11-44. PMC 2865488. PMID 20346144.
- ^ Citti C, Russo F, Linciano P, Strallhofer SS, Tolomeo F, Forni F, et al. (2021). "Origin of Δ9-Tetrahydrocannabinol Impurity in Synthetic Cannabidiol". Cannabis and Cannabinoid Research. 6 (1): 28–39. doi:10.1089/can.2020.0021. PMC 7891213. PMID 33614950.